Presentations by Event

Cefpodoxime-ETX1317 Susceptibility is Unaffected by Ceftazidime-Avibactam Resistance Mutations V240G, D179Y and D179Y/T243M in KPC-3 β-Lactamase

Shapiro AB, Moussa SH, Carter NM, Gao N and Miller AA (Microbe 2019)

Program(s): etx0282

Novel Therapies Targeting Drug-Resistant Gonorrhea

Mueller JP (Microbe 2019)

Program(s): zoliflodacin (etx0914)

Scientific Overview of Entasis Pipeline

Tommasi R (Microbe 2019)

The Novel β-lactamase Inhibitor ETX1317 Restores the Activity of Cefpodoxime Against Drug-Resistant Enterobacteriaceae

McLeod S, Carter N, Moussa S, Mueller J, Tommasi R and Miller A (Microbe 2019)

Program(s): etx0282

Pharmacokinetics/Pharmacodynamics and Phase 3 Dose Projection For the Novel β-lactamase Inhibitor ETX2514 in Combination with Sulbactam Against Acinetobacter baumannii calcoaceticus Complex (ABC)

O'Donnell J (Microbe 2019)

Program(s): durlobactam (etx2514)

The Novel β-lactamase Inhibitor ETX2514 Restores Sulbactam Activity against Recent, Globally Diverse Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Huband M, Edah Y, Tommasi R and Miller A (Microbe 2019)

Program(s): durlobactam (etx2514)

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)

Program(s): durlobactam (etx2514)

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Srinivasan S (ECCMID 2019))

Program(s): durlobactam (etx2514)

Efficacy of Cefpodoxime Proxetil and ETX0282 in a Murine UTI Model with E. coli and K. pneumoniae

Weiss WJ, Carter K, Pulse ME, Nguyen P, Valtierra D, Peterson K, Tommasi R, Mueller JP, O'Donnell J (ECCMID 2019)

Program(s): etx0282

Discovery of a Novel Series of Penicillin-Binding Protein 3 Inhibitors as Monotherapy for Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T (ECCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Recent Global Enterobacteriaceae Isolates from Urinary Tract Infections

McLeod S, Moussa S, Huband M, Mueller J, Tommasi R and Miller A (ECCMID 2019)

Program(s): etx0282

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M, Tommasi R and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Seifert H, Stefanik, D, Muller C, Higgins P, Kresken M and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)

ETX2514SUL (Sulbactam/ETX2514) for The Treatment of Acinetobacter baumannii Infection

Isaacs R (IDWeek 2018)

Program(s): durlobactam (etx2514)